FDA concludes examination of Parkinson's drug

The Food and Drug Administration announced Thursday it had not identified any "new or unexpected safety find...

Posted: Sep 21, 2018 10:50 AM
Updated: Sep 21, 2018 10:50 AM

The Food and Drug Administration announced Thursday it had not identified any "new or unexpected safety findings" related to a drug used to treat psychosis in Parkinson's patients, though it did find potentially troubling prescribing practices.

Nuplazid, which hit the market in 2016, is the only medication approved to treat hallucinations and delusions associated with a debilitating condition known as Parkinson's disease psychosis. It has been cited as a "suspect" medication in hundreds of deaths voluntarily reported to the agency, as highlighted in a CNN report earlier this year.

Business and industry sectors

Business, economy and trade

Diseases and disorders

Government organizations - US

Health and medical

Neurological disorders and injuries

Parkinson's disease

Pharmaceutical industry

Pharmaceuticals and biotechnology

Pharmaceuticals and prescription drugs

US Department of Health and Human Services

US federal departments and agencies

US Food and Drug Administration

Medical experts told CNN at the time that the high number of so-called "adverse event reports" deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.

Nuplazid's initial review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.

After CNN published its investigation on Nuplazid, reporters were contacted by family members who said they believed the drug contributed to their loved one's decline or death. Others said Nuplazid helped tame hallucinations with few apparent side effects.

The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.

On Thursday, the FDA said it had completed a review of these deaths and other adverse events that had been reported to the agency.

"Overall, the postmarketing data were consistent with the safety data obtained from the premarketing controlled clinical trials of Nuplazid for Parkinson's disease psychosis," it stated.

Acadia Pharmaceuticals, the company that manufactures Nuplazid, welcomed the FDA findings. "Nothing is more important to Acadia than the wellbeing of the patients who use Nuplazid," Steve Davis, the company's president and chief executive officer, said in a statement. "We are very pleased with the FDA's clear statement reaffirming Nuplazid's positive benefit-risk profile."

Dr. Paul Andreason, the physician who led the FDA's initial medical review of Nuplazid, had warned at the time of Nuplazid's approval that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.

In its statement this week, the FDA noted that like other antipsychotics, the drug already has the agency's most severe "black box" warning about the increased risk of death for the treatment of elderly dementia patients.

The agency also said its review had found "potentially concerning prescribing patterns," such as the use of Nuplazid with other antipsychotic drugs or with medications that can cause heart issues. It urged health care providers to familiarize themselves with the warnings and precautions associated with Nuplazid when prescribing it to patients.

The FDA said it would continue to monitor reports of adverse events and encouraged patients and doctors to report any suspected side effects to the agency.

Do you have information to share about Nuplazid or other drugs targeting the elderly? Email us: watchdog@cnn.com.

This story has been updated with a statement from Acadia Pharmaceuticals.

Minnesota Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 26980

Reported Deaths: 1159
CountyConfirmedDeaths
Hennepin9099657
Ramsey3351149
Stearns205614
Nobles15775
Anoka152779
Dakota144664
Washington70035
Olmsted68911
Rice5243
Kandiyohi5141
Scott4712
Clay44930
Mower4462
Wright3492
Todd3441
Sherburne2492
Carver2402
Benton1853
Steele1700
Freeborn1590
Blue Earth1490
Martin1355
St. Louis11914
Lyon1012
Unassigned9611
Pine930
Nicollet8811
Cottonwood820
Winona8115
Crow Wing815
Watonwan790
Carlton750
Goodhue736
Otter Tail731
Chisago691
Polk632
Itasca5610
Dodge540
Chippewa521
Morrison480
Le Sueur471
Douglas460
Meeker460
Becker440
Jackson420
Murray410
McLeod410
Isanti360
Pennington300
Waseca290
Mille Lacs241
Rock230
Faribault220
Wabasha200
Swift191
Beltrami180
Sibley170
Brown172
Fillmore171
Norman150
Pipestone130
Kanabec121
Aitkin120
Marshall120
Cass112
Big Stone110
Wilkin113
Wadena100
Pope100
Koochiching90
Redwood70
Yellow Medicine70
Renville70
Mahnomen61
Lincoln60
Red Lake40
Traverse40
Grant40
Clearwater30
Houston30
Hubbard30
Lac qui Parle30
Roseau30
Stevens10
Lake10
Kittson10

Iowa Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 21114

Reported Deaths: 593
CountyConfirmedDeaths
Polk4614140
Woodbury286137
Black Hawk178849
Buena Vista10672
Linn97879
Dallas95226
Marshall91418
Wapello63615
Johnson6198
Muscatine56741
Crawford5512
Tama41129
Scott38510
Dubuque35921
Louisa35011
Pottawattamie31910
Sioux3060
Jasper26917
Wright2210
Washington1968
Warren1671
Plymouth1522
Story1311
Allamakee1204
Mahaska9913
Poweshiek928
Hamilton760
Webster741
Henry732
Boone720
Bremer716
Clarke690
Des Moines681
Taylor660
Clinton651
Guthrie553
Cedar501
Benton431
Cherokee410
Monroe415
Jones370
Shelby370
Osceola360
Jefferson360
Marion350
Dickinson350
Buchanan341
Iowa340
Clayton343
Cerro Gordo331
Madison292
Lee290
Sac280
Davis280
Emmet270
Fayette270
Clay270
Monona260
Harrison260
Hardin240
Lyon240
Winneshiek240
Lucas222
Mills200
Grundy200
Franklin200
Humboldt201
Pocahontas200
Delaware191
Floyd191
Hancock180
Appanoose173
Butler161
Kossuth160
Carroll151
Ida150
Greene150
Keokuk140
Jackson140
Page140
Audubon131
Cass130
Chickasaw130
Howard120
Winnebago110
Calhoun100
Union100
Van Buren90
Adair90
Montgomery92
Adams70
Palo Alto70
Ringgold40
Fremont40
Mitchell40
Worth30
Unassigned20
Wayne10
Decatur10
Rochester
Few Clouds
77° wxIcon
Hi: 79° Lo: 61°
Feels Like: 78°
Mason City
Scattered Clouds
82° wxIcon
Hi: 82° Lo: 64°
Feels Like: 82°
Albert Lea
Clear
81° wxIcon
Hi: 81° Lo: 65°
Feels Like: 81°
Austin
Broken Clouds
81° wxIcon
Hi: 81° Lo: 65°
Feels Like: 81°
Charles City
Clear
81° wxIcon
Hi: 82° Lo: 62°
Feels Like: 81°
Weekend looks nice
KIMT Radar
KIMT Eye in the sky

Latest Video

Image

Chris' PM Weather Forecast 6/5

Image

Gyms, fitness centers set to reopen

Image

Easing restrictions for MN restaurants and gyms

Image

Charles City vigil for George Floyd

Image

Hawkeye Harvest Foodbank partnership

Image

Next phase of Minnesota reopening

Image

Rental Assistance program for Rochester

Image

IA Care Homes Could Reopen to Visitors

Image

'Color Me Mine' Location Closes for Good

Image

Getting Your Fair Food Fix During the Pandemic

Community Events